Schizophrenia is a serious condition that affects many people. Finding it early can change lives. A large review looked at how artificial intelligence might help doctors see the signs sooner. The team examined 185 different studies that used brain imaging data. They focused on methods like machine learning and deep learning to find patterns in MRI, PET, and EEG scans. These tools aim to predict the condition before symptoms become severe. The research also looked at how well these models identify specific biomarkers and choose the best diagnostic approaches. Safety was not a focus because these are computer tools, not drugs. However, the authors noted that challenges and limitations exist in these models. They also highlighted research gaps that need more work. Despite these hurdles, the findings support using technology to help individuals affected by schizophrenia get timely interventions. This review brings together a vast amount of data to show where we stand today.
Systematic review of AI for schizophrenia prediction using medical imaging dataAI tools may help predict schizophrenia using brain scans from 185 studies
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This systematic literature review evaluates 185 studies that utilize artificial intelligence methodologies, specifically machine learning and deep learning, in conjunction with medical imaging data including MRI, PET, and EEG. The scope of the review encompasses the prediction of schizophrenia, biomarker identification, model selection, and diagnostic accuracy within this technological context. The authors do not report specific adverse events or tolerability data as these were not included in the source material.
The synthesis of these 185 studies reveals significant challenges and limitations inherent to machine learning and deep learning models when applied to psychiatric imaging. The review does not establish causal relationships or provide specific numerical effect sizes, as the primary results were not reported in the source data. Instead, the authors focus on the methodological hurdles and the current state of research gaps in this field.
The practice relevance identified by the authors suggests that these technologies may support timely interventions for individuals affected by schizophrenia. However, the review does not provide definitive clinical guidelines or specific safety profiles. The certainty of these conclusions is constrained by the nature of the literature review and the lack of reported follow-up durations or specific study settings.